Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Incyte (INCY) -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (758)	10/29/1998 4:56:00 PM
From: Rocketman	Read Replies (2) \| Respond to of 3202

I seriously doubt that this lawsuit would ever have an adverse effect on INCY. INCY has always consistently tried to source stuff from places other than PKN so they don't get price gouged as PKN is prone to do. Plus, INCY has been phasing out the PKN machines for a long time now (and as of their annual meeting last spring had completely depreciated all of their ABI sequencers), switching over to the Molecular Dynamics MegaBace systems which are way ahead of anything PKN has to offer at this time. And, since Amersharm-Pharmacia has bought Molecular Dynamics, I don't see how this could possibly hurt INCY, who has to be one of their biggest and best customers. If anything, it could possibly help INCY by impeding PKN and PKN:TIGR's Celera in their attempts to compete with INCY. I don't know if the PKN sequencers under development would fall under this lawsuit. But, as far as I am concerned, PKN is playing catch up with Molecular Dynamics (and hence INCY) who has a couple of year head start on 96 capillary electrophoresis sequencers. The press coverage has seemed to ignore this fact, focusing only on PKN's pronouncements, but my feeling is that PKN is way late in the game and doing nothing but pissing on their customers by trying to compete with them rather than staying happy as a supplier. My guess is that they get crushed in the competitive marketplace. PKN doesn't have anywhere as deep of pockets as Amersham-Pharmacia. By buying Molecular Dynamics, A-P brings a new dyanmic to this game, and it is decidedly in their favor. Rman